In a 3-year extension of the pivotal trials that provided lebrikizumab with an indication for atopic dermatitis, the response ...

Eli Lilly's Ebglyss gains FDA approval for atopic dermatitis treatment, poised to rival Dupixent with strong performance in ...

Atopic Dermatitis, commonly called Eczema, affects millions globally with cases rising in India. Misunderstandings about its ...

Discover research presented at EADV 2024 highlighting the significant impact of atopic dermatitis on psychological and social ...

Thermo Fisher Scientific Inc., the world leader in serving science, today announced the launch of the international CorEvitas Adolescent Atopic Dermatitis (AD) Registry, designed to study novel ...

Ebglyss is a new biologic treatment for moderate-to-severe eczema that isn’t controlled with topical therapies. The ...

Galderma today announced that it will present new data from the ARCADIA and OLYMPIA clinical trial programs investigating ...

EBGLYSS is an FDA-approved drug for treating moderate-to-severe eczema by targeting IL-13, offering relief to patients ...

The U.S. Food and Drug Administration has approved Eli Lilly's Ebglyss (lebrikizumab-lbkz) for adults and children aged 12 ...

Organon acquires ROIV's Dermavant for $1.2B, expanding their dermatology portfolio and potentially increasing sales. Click ...

(RTTNews) - Arcutis Biotherapeutics Inc.'s (ARQT) ZORYVE cream 0.15% provided consistent and meaningful improvements in signs and symptoms of atopic dermatitis in individuals regardless of race, ...

LEO Pharma A/S, a global leader in medical dermatology, today announced positive results from the Phase 2a Mechanism of Action (MoA) trial, which assessed the mechanistic impact of investigational ...